(Q37841269)

24 August 2017

2 references

23 October 2022

Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention (English)

1 reference

24 August 2017

0 references

Jessie R Groothuis

1

1 reference

24 August 2017

J Michael Hoopes

series ordinal

2

1 reference

24 August 2017

Val G Hemming Jessie

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

4 February 2011

1 reference

24 August 2017

1 February 2011

1 reference

23 October 2022

2 references

24 August 2017

23 October 2022

28

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

91-109

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-010-0100-z

24 August 2017

exact match

0 references

cites work

Respiratory syncytial virus and parainfluenza virus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory morbidity in adulthood after respiratory syncytial virus hospitalization in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Association of the chimpanzee coryza agent with acute respiratory disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Epidemic bronchiolitis and pneumonitis related to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus in Britain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Acute respiratory diseases of viral etiology. IV. Respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Immunity to and frequency of reinfection with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Maternal antibody and respiratory syncytial virus infection in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

"Late-preterm" infants: a population at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Viral respiratory infections in children with technology dependence and neuromuscular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Viral and host factors in human respiratory syncytial virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

The progression of maternal RSV antibodies in the offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

In search of a vaccine for respiratory syncytial virus: the saga continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Immunopathology of RSV infection: prospects for developing vaccines without this complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Challenges in developing a pediatric RSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Experimental models for study of common respiratory viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0100-Z

Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization.

21 January 2018

1 reference

12 December 2020

Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children.

1 reference

12 December 2020

Mechanisms of immunity to respiratory syncytial virus in cotton rats

1 reference

12 December 2020

Respiratory syncytial virus vaccines

1 reference

12 December 2020

Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

1 reference

12 December 2020

Isolation of the respiratory syncytial virus from a patient with pneumonia.

1 reference

12 December 2020

The pathogenesis of respiratory syncytial virus infection in infant ferrets

1 reference

12 December 2020

Experimental RS virus infection of cotton rats. A viral and immunofluorescent study

1 reference

12 December 2020

The pathogenesis of respiratory syncytial virus infection in cotton rats

1 reference

12 December 2020

Repeated infections with respiratory syncytial virus

1 reference

12 December 2020

New insights for development of a safe and protective RSV vaccine

1 reference

12 December 2020

Studies of acute respiratory illnesses caused by respiratory syncytial virus. 1. Laboratory findings in 109 cases.

1 reference

12 December 2020

Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease

1 reference

12 December 2020

Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis

1 reference

12 December 2020

Serum-gamma-G-globulin levels in normal premature, post-mature, and "small-for-dates" newborn babies

1 reference

12 December 2020

Recovery of cytopathogenic agent from chimpanzees with coryza

1 reference

12 December 2020

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

12 December 2020

Experimental infection with respiratory syncytial virus in several species of animals

1 reference

12 December 2020

Respiratory syncytial virus. II. Serologic studies over a 34-month period of children with bronchiolitis, pneumonia, and minor respiratory diseases.

1 reference

12 December 2020

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

12 December 2020

Risk of primary infection and reinfection with respiratory syncytial virus

1 reference

12 December 2020

Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection

1 reference

12 December 2020

Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children

1 reference

12 December 2020

Respiratory syncytial virus infection in children with bronchopulmonary dysplasia

1 reference

12 December 2020

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

1 reference

12 December 2020

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

1 reference

12 December 2020

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

12 December 2020

Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

1 reference

12 December 2020

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Advances in respiratory syncytial virus vaccine development.

1 reference

12 December 2020

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

1 reference

12 December 2020

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

12 December 2020

An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection

1 reference

12 December 2020

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

12 December 2020

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

1 reference

12 December 2020

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

12 December 2020

10.1007/S12325-010-0100-Z

Identifiers

DOI

1 reference

24 August 2017

0 references

1 reference